Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, Multi-center Phase II Study to Evaluate the Efficacy and Safety of AHB-137 in HBeAg-negative CHB Subjects Under Stable Nucleos(t)Ide Analogue (NA) Treatment

Trial Profile

Randomized, Multi-center Phase II Study to Evaluate the Efficacy and Safety of AHB-137 in HBeAg-negative CHB Subjects Under Stable Nucleos(t)Ide Analogue (NA) Treatment

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 22 Nov 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AHB 137 (Primary)
  • Indications Hepatitis B
  • Focus Therapeutic Use
  • Sponsors AusperBio

Most Recent Events

  • 05 Nov 2026 According to an AusperBio media release,data from this trial will be presented at The Liver Meeting 2026, the annual meeting of the American Association for the Study of Liver Diseases (AASLD), taking place November 5 to 9 in Denver, Colorado.
  • 15 Sep 2026 Status changed from active, no longer recruiting to completed.
  • 07 May 2026 Planned End Date changed from 30 Jun 2026 to 1 Oct 2026.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top